Biotech IPOs, Avalon & FDA at SCOTUS: a BioCentury podcast

Plus: assessing FDA’s first complete response letter for lack of confirmatory trial enrollment

Upcoming catalysts could drive value creation at NASDAQ’s newest biotech,  Boundless Bio Inc. (NASDAQ:BOLD), after it stumbled in its trading debut last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss Boundless’ IPO in the context of the current market for fresh paper and profile the “sweat equity” model of Avalon BioVentures, the VC firm led by Jay Lichter.

Turning to Washington, BioCentury’s editors assess possible outcomes for the Supreme Court case on abortion drug mifepristone, and why the court’s pending decision could safeguard FDA from judicial second-guessing. The team also analyzes the agency’s first ever complete response letter for lack of confirmatory trial enrollment.

For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.